What type of study is this?

September 5, 2025Open Access

Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

CAR T-cells effectively reduced myeloma growth, even under limited BCMA expression.
The key metric was cytokine production, specifically IFNγ and IL-2, measured at 24 hours.
Observational analysis showed cytokine levels in CAR T-cells after co-culturing with K562 tumor cells.
Findings suggest potential for CAR T-cells in cases with variable BCMA expression, requiring further validation.

Implication

Cytokine production improved in co-cultured CAR T-cells against BCMA and CD229, indicating effective myeloma management.

Abstract

Cytokine production (IFNγ and IL-2) of CAR T-cells in co-culture with K562 cell lines with different expression of CD229 antigen tumor cells at the 24-hr time point measured by ELISA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b77 https://doi.org/10.1158/2326-6066.30029626

View Full Paper

Ask AI

Bookmark

Implication

Cytokine production improved in co-cultured CAR T-cells against BCMA and CD229, indicating effective myeloma management.

Abstract

Cytokine production (IFNγ and IL-2) of CAR T-cells in co-culture with K562 cell lines with different expression of CD229 antigen tumor cells at the 24-hr time point measured by ELISA.

Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading